Keytruda pembrolizumab: Phase II ongoing

Merck’s Keytruda pembrolizumab will be evaluated in the ongoing Phase II I-SPY 2 trial, which is designed to rapidly and inexpensively test compounds in biomarker-defined subgroups of patients with

Read the full 293 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE